Trial of VLTS-934 in Subjects With Intermittent Claudication Secondary to Peripheral Arterial Disease
Status:
Completed
Trial end date:
2006-07-01
Target enrollment:
Participant gender:
Summary
This is a phase II, multicenter, randomized, double-blind, placebo-controlled trial in which
subjects with intermittent claudication (IC) will be randomized to receive a single treatment
of VLTS-934 (84 mL, or a total of 420 mg poloxamer 188) or placebo (84 mL saline)
administered as 21 intramuscular (IM) injections of 2 mL each, bilaterally into the lower
extremities during one procedure to evaluate the safety, tolerability, and potential activity
of VLTS-934 as compared with a saline placebo.